Elevance Health, Inc. - Common Stock (ELV)

Historical Holders from Q1 2014 to Q4 2025

Symbol: ELV on NYSE
Type / Class: Equity / Common Stock
Shares outstanding: 225,970,109
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 195,469,146
Holdings value: $63,175,640,130
% of all portfolios: 0.06%
Number of holders: 1,488
Number of buys: 675
Number of sells: 820
Average buys %: +0.02%
Average sells %: -0.01%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Elevance Health, Inc. - Common Stock (ELV) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
VANGUARD GROUP INC	10%		$9,468,767,838		22,890,772		The Vanguard Group	30 Apr 2025
BlackRock, Inc.	7.8%		$7,319,395,282		17,694,658		BlackRock, Inc.	31 Mar 2025

As of 30 Sep 2025 Elevance Health, Inc. - Common Stock (ELV) has 1,488 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 195,469,146 shares of 225,970,109 outstanding shares and own 87% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of Elevance Health, Inc. - Common Stock (ELV) own 55% of the company based on 13F filings as of 30 Sep 2025

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
VANGUARD GROUP INC	10%	22,998,645	+0.62%	0.11%	$7,431,322,172
BlackRock, Inc.	9.1%	20,533,269	+0.59%	0.12%	$6,634,710,108
STATE STREET CORP	4.6%	10,346,169	-2.1%	0.12%	$3,343,054,127
WELLINGTON MANAGEMENT GROUP LLP	2.9%	6,621,297	+4.8%	0.37%	$2,139,473,488
PRICE T ROWE ASSOCIATES INC /MD/	2.6%	5,838,911	-28%	0.2%	$1,886,670,000
Sanders Capital, LLC	2.6%	5,768,918	-0.97%	2.3%	$1,864,052,784
GEODE CAPITAL MANAGEMENT, LLC	2.3%	5,143,904	+0.98%	0.11%	$1,661,179,878
Artisan Partners Limited Partnership	2%	4,576,805	+25%	2.1%	$1,478,857,232
First Eagle Investment Management, LLC	1.8%	3,998,603	+25%	2.4%	$1,292,028,537
HARRIS ASSOCIATES L P	1.4%	3,189,624	+39%	1.7%	$1,030,631,439
Capital International Investors	1.3%	2,954,717	-54%	0.15%	$954,566,722
MORGAN STANLEY	1.2%	2,683,650	-12%	0.05%	$867,142,353
Invesco Ltd.	1.1%	2,597,488	+23%	0.13%	$839,300,364
BANK OF AMERICA CORP /DE/	1.1%	2,595,732	+19%	0.06%	$838,732,984
Grantham, Mayo, Van Otterloo & Co. LLC	1.1%	2,523,450	+24%	2.3%	$815,377,419
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	1.1%	2,440,630	+4.8%	0.24%	$788,616,366
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC	1.1%	2,386,059	-20%	0.17%	$770,983,385
NORTHERN TRUST CORP	1%	2,277,649	-2.1%	0.09%	$735,953,944
MANUFACTURERS LIFE INSURANCE COMPANY, THE	0.98%	2,213,870	+6.6%	0.59%	$715,345,658
BAILLIE GIFFORD & CO	0.96%	2,166,914	-3.1%	0.52%	$700,173,251
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC	0.91%	2,045,480	+44%	2%	$660,935,498
Nuveen, LLC	0.86%	1,948,118	+2%	0.17%	$629,475,795
Legal & General Group Plc	0.85%	1,921,353	+4.8%	0.14%	$620,827,581
Brave Warrior Advisors, LLC	0.81%	1,834,002	+65%	14%	$592,602,726
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.75%	1,686,220	-6.6%	0.09%	$544,851,406

Institutional Holders of Elevance Health, Inc. - Common Stock (ELV) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	62,699	$21,982,158	+$1,720,847			$350.55	33
2025 Q3	195,469,146	$63,175,640,130	-$3,318,725,468	$697,330,438	$803,924,318	$323.12	1,488
2025 Q2	204,604,844	$79,498,363,022	+$1,439,627,570	$418,910,620	$591,403,124	$388.96	1,568
2025 Q1	200,691,838	$87,287,919,928	-$2,163,798,151	$467,526,331	$714,071,240	$434.96	1,638
2024 Q4	206,213,996	$75,993,957,146	-$44,680,642	$482,262,364	$552,698,766	$368.90	1,579
2024 Q3	204,337,175	$106,108,060,305	-$2,056,527,998	$535,691,385	$534,185,840	$520.00	1,677
2024 Q2	207,236,343	$112,229,086,782	+$1,221,818,434	$545,803,056	$554,463,305	$541.86	1,694
2024 Q1	205,794,945	$106,687,848,409	-$1,247,923,452	$562,168,898	$570,912,434	$518.54	1,653
2023 Q4	207,752,105	$97,963,233,994	-$247,874,299	$601,628,443	$560,804,265	$471.56	1,648
2023 Q3	207,903,581	$90,580,448,880	-$638,821,702	$458,112,253	$379,931,715	$435.42	1,517
2023 Q2	209,210,262	$92,957,672,062	-$418,252,067	$362,641,099	$409,875,763	$444.29	1,513
2023 Q1	210,263,353	$96,683,749,324	-$1,143,379,932	$378,726,936	$362,354,947	$459.81	1,505
2022 Q4	212,710,438	$109,036,688,386	-$450,450,567	$581,510,603	$483,814,728	$512.97	1,535
2022 Q3	213,712,340	$97,144,686,967	-$43,691,666	$571,485,000	$527,728,000	$454.24	1,419
2022 Q2	213,631,648	$103,081,919,033	+$244,924,540	$521,859,734	$476,642,293	$482.58	1,427
2022 Q1	214,741,635	$105,507,397,690	+$476,326,109	$439,732,000	$400,932,000	$491.22	1,405
2021 Q4	213,774,296	$99,066,091,155	-$693,430,737	$656,356,000	$582,370,000	$463.54	1,356
2021 Q3	215,444,748	$80,367,417,712	-$316,844,753	$522,884,080	$600,491,200	$372.80	1,200
2021 Q2	216,259,288	$82,538,173,898	-$202,615,221	$451,267,780	$515,017,620	$381.80	1,218
2021 Q1	217,018,977	$77,891,055,351	-$10,123,479	$627,544,000	$539,145,000	$358.95	1,197
2020 Q4	216,717,748	$69,548,509,680	-$1,210,346,982	$599,214,085	$475,241,720	$321.09	1,152
2020 Q3	221,726,205	$59,513,110,228	-$812,067,541	$588,807,000	$575,924,000	$268.59	1,069
2020 Q2	224,433,586	$58,976,107,586	+$721,554,198	$678,539,000	$594,243,000	$262.98	1,087
2020 Q1	221,960,038	$50,395,003,088	-$269,286,785	$355,285,000	$358,171,000	$227.04	1,024
2019 Q4	222,498,992	$67,185,310,864	-$895,364,531	$504,151,000	$489,709,000	$302.03	1,091
2019 Q3	225,668,191	$54,151,556,112	-$548,766,172	$432,315,000	$356,338,000	$240.10	1,000
2019 Q2	227,616,918	$64,170,095,418	+$1,536,564,497	$444,482,000	$540,090,000	$282.21	1,017
2019 Q1	226,368,216	$64,895,946,969	-$571,793,174	$270,879,000	$372,184,000	$286.98	1,060
2018 Q4	228,485,511	$59,953,636,310	+$649,953,066	$181,178,000	$583,380,000	$262.63	981
2018 Q3	227,218,938	$62,202,902,147	-$82,133,140	$225,872,000	$447,114,000	$274.05	935
2018 Q2	227,862,596	$54,180,142,736	+$475,345,916	$154,662,000	$336,239,000	$238.03	917
2018 Q1	226,170,388	$49,620,249,094	+$136,418,805	$187,997,040	$270,516,090	$219.70	914
2017 Q4	226,383,870	$50,867,636,678	-$185,837,358	$204,032,000	$138,972,000	$225.01	904
2017 Q3	227,037,673	$43,110,236,091	-$979,896,912	$206,777,000	$153,504,900	$189.88	836
2017 Q2	234,666,772	$44,173,109,626	-$691,902,449	$171,507,000	$139,416,000	$188.13	842
2017 Q1	237,409,781	$39,276,632,137	+$4,215,665,646	$150,556,000	$206,916,000	$165.38	782
2016 Q4	236,826,614	$34,047,895,479	+$101,419,844	$128,501,000	$132,884,000	$143.77	774
2016 Q3	233,767,626	$29,277,751,316	-$472,226,246	$136,517,000	$108,850,000	$125.31	720
2016 Q2	237,434,049	$31,183,934,688	+$185,770,985	$91,790,000	$94,261,000	$131.34	747
2016 Q1	235,568,359	$32,735,981,567	-$98,831,773	$79,446,000	$70,450,000	$138.99	757
2015 Q4	236,580,508	$32,994,086,121	+$245,535,016	$97,697,000	$134,590,000	$139.44	752
2015 Q3	234,763,359	$32,864,234,259	+$972,586,432	$122,122,000	$118,153,000	$140.00	747
2015 Q2	227,776,038	$37,381,525,830	-$957,364,602	$527,422,000	$142,999,000	$164.14	771
2015 Q1	233,007,822	$35,964,678,637	-$91,145,105	$261,339,000	$97,900,000	$154.41	739
2014 Q4	234,612,259	$29,496,786,731	+$29,380,309,696	$241,972,000	$105,476,000	$125.67	697
2014 Q3	60,821	$7,275,000				$119.61	1
2014 Q2	60,821	$6,544,000	+$615,978			$107.59	1
2014 Q1	55,096	$5,484,000	+$2,384,868			$99.54	1